Trials / Completed
CompletedNCT02422927
Nutraceutical Combination in Patients With Low-grade Systemic Inflammation
Effect of a Nutraceutical Combination on Endothelial Injury and C-reactive Protein in Patients With Low-grade Systemic Inflammation
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- University Of Perugia · Academic / Other
- Sex
- All
- Age
- 25 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The investigators tested if a nutraceutical combination with red yeast rice, berberine and policosanol (NC) can significantly modify inflammation, lipid profile and markers of endothelial injury (endothelial microparticles) in subjects with elevated levels of high-sensitivity C-reactive protein (hsCRP).
Detailed description
Will be included in the study 100 subjects with suboptimal LDL cholesterol levels (LDL 100-160 mg / dL) and hsCRP levels\> 2 mg / L, divided into two groups of equal numbers, matched by by sex and age, randomized to receive a nutraceutical combination containing red yeast 200 mg, berberine 500 mg and policosanol 10 mg (NC) in combination with a low-cholesterol diet (\<200 mg / day) or a low-cholesterol diet only (Standard of Care - SOC). All subjects at the time of inclusion in the study protocol will be prescribed the SOC for a period of 30 days (Lipid Stabilization Period: LSP); After 30 days LSP it will be performed randomization in the two intervention arms: NC + SOC or SOC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Nutraceutical Combination | red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily |
| OTHER | Standard of Care | low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule |
| OTHER | Placebo | placebo |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-01-01
- Completion
- 2015-02-01
- First posted
- 2015-04-22
- Last updated
- 2015-04-22
Source: ClinicalTrials.gov record NCT02422927. Inclusion in this directory is not an endorsement.